OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

SWEDISH ORPHAN BIOVITRUM AB/  SE0000872095  /

Turquoise
2024-08-09  5:22:30 PM Chg. +2.70 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
278.70SEK +0.98% 8,566
Turnover: 2.37 mill.		 -Bid Size: - -Ask Size: - 98.65 bill.SEK - 37.27
GlobeNewswire 07-01 ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
GlobeNewswire 06-27 ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
GlobeNewswire 06-03 ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
GlobeNewswire 05-30 ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire 05-24 Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
GlobeNewswire 05-24 Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Act...
GlobeNewswire 05-15 ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at ...
GlobeNewswire 05-09 ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
GlobeNewswire 05-06 ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire 05-06 ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLON...
GlobeNewswire 05-01 ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on...
GlobeNewswire 04-04 ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination wit...
GlobeNewswire 04-03 ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
GlobeNewswire 04-01 Autolus Therapeutics Announces Changes to its Board of Directors
GlobeNewswire 03-28 Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
GlobeNewswire 03-13 ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business U...
GlobeNewswire 03-06 ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
GlobeNewswire 03-06 ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March...
GlobeNewswire 03-05 ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cance...
GlobeNewswire 01-04 ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
GlobeNewswire 01-04 ADC Therapeutics Provides Business Updates
GlobeNewswire 2023-12-12 ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evalua...
GlobeNewswire 2023-11-07 ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
GlobeNewswire 2023-11-07 ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
GlobeNewswire 2023-11-06 Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia